Business
RepliCel Receives European Patent for its Innovative Dermal Injector Technology
RepliCel Receives European Patent for its Innovative Dermal Injector Technology.
About this update from Replicel Life Sciences Inc.
[{"type":"text","content":"\n \n \n RepliCel Receives European Patent for its Innovative Dermal Injector Technology\n \n \nRepliCel Receives European Patent for its Innovative Dermal Injector Technology\n\nRCI-02 injector device promises the potential for unparalleled injection precision, the use of less anesthetic per procedure, and the enhanced treatment of fine wrinkles of the face, décolleté and hands\n\n \n VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan 11, 2016) - RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSX VENTURE:RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced that it has been granted a patent (EP2623146) by the European Patent Office for its injection device technologies. The first device being developed under this patent, RCI-02, is designed for injecting hyaluronic acid as a dermal filler. The device is also being developed for the injection of RepliCel's RCH-01 hair restoration and RCS-01 skin rejuvenation products. Future iterations of the technology and device will be optimized for other injectables such as drugs, vaccines, fat grafts, etc.\n \"This patent grant is an important milestone for the company as it underpins the commercial value of RCI-02 for the delivery of other injectables beyond our own products. RCI-02 coupled with an application in the area of hyaluronic acid (HA) represents an early opportunity for licensing and revenue,\" stated RepliCel CEO Lee Buckler. \n Overall benefits of this next-generation dermal injector technology include improved handling, reduction or elimination of the need for local anesthetic, quicker procedure times, an expectation of more consistent clinical results because of the injector's controls, and a significant expansion of the areas that can be addressed with dermal fillers due to the ability to conduct broad, shallow, and evenly-dispersed injections. Additionally, it is expected that a whole new class of injection specialists may be enabled to perform certain dermal injection procedures due to the device's simplicity and programmability. \n \"RCI-02 was originally conceived to deliver our cellular products; however, we believe this device will have a profound impact on all dermal injections - particularly in the cosmetic dermal injection market,\" commented Dr. Rolf Hoffmann, RepliCel's Chief Medical Officer...